|
1
|
Hobbs BD, Putman RK, Araki T, Nishino M,
Gudmundsson G, Gudnason V, Eiriksdottir G, Zilhao Nogueira NR,
Dupuis J, Xu H, et al: Overlap of genetic risk between interstitial
lung abnormalities and idiopathic pulmonary fibrosis. Am J Respir
Crit Care Med. 200:1402–1413. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Pereira CAC, Soares MR, Boaventura R,
Castro MDC, Gomes PS, Gimenez A, Fukuda C, Cerezoli M and Missrie
I: Squawks in interstitial lung disease prevalence and causes in a
cohort of one thousand patients. Medicine (Baltimore).
98(e16419)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Singh P, Thakur B, Mohapatra AK and Padhan
P: Clinical features and outcome of acute exacerbation in
connective tissue disease-associated interstitial lung disease: A
single-center study from India. Int J Rheum Dis. 22:1741–1745.
2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gasperini ML, Gigante A, Iacolare A,
Pellicano C, Lucci S and Rosato E: The predictive role of lung
ultrasound in progression of scleroderma interstitial lung disease.
Clin Rheumatol. 39:119–123. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Willemsen AECAB, Tol J, van Erp NP, Jonker
MA, de Boer M, Meek B, de Jong PC, van Moorsel C, Gerritsen WR,
Grutters JC and van*Herpen CML: Prospective study of drug-induced
interstitial lung disease in advanced breast cancer patients
receiving everolimus plus exemestane. Target Oncol. 14:441–451.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Saito S, Alkhatib A, Kolls JK, Kondoh Y
and Lasky JA: Pharmacotherapy and adjunctive treatment for
idiopathic pulmonary fibrosis (IPF). J Thorac Dis. 11 (Suppl
14):S1740–S1754. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ussavarungsi K, Nugent K, Gerke AK,
Krasowski MD, Tuetken RS and Lenert PS: Interstitial lung disease
associated with anti-PM-Scl antibody: A single center experience.
Autoimmun Rev. 18(102355)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chai GT, Tan TC, Lee YS, Kaw GJ, Chuah KL,
Lim YJ, Abisheganaden JA and Thong BY: Impact of an interstitial
lung disease service in the diagnosis and management of
interstitial lung disease in Singapore. Singapore Med J.
61:302–307. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chen Z, Wang X and Ye S: Tofacitinib in
Amyopathic Dermatomyositis-associated interstitial lung disease. N
Engl J Med. 381:291–293. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hoffmann-Vold AM, Fretheim H, Halse AK,
Seip M, Bitter H, Wallenius M, Garen T, Salberg A, Brunborg C,
Midtvedt Ø, et al: Tracking impact of interstitial lung disease in
systemic sclerosis in a complete nationwide cohort. Am J Respir
Crit Care Med. 200:1258–1266. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ye Y, Fu Q, Wang R, Guo Q and Bao C: Serum
KL-6 level is a prognostic marker in patients with anti-MDA5
antibody-positive dermatomyositis associated with interstitial lung
disease. J Clin Lab Anal. 33(e22978)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lee JU, Son JH, Shim EY, Cheong HS, Shin
SW, Shin HD, Baek AR, Ryu S, Park CS, Chang HS and Park JS: Global
DNA methylation pattern of fibroblasts in idiopathic pulmonary
fibrosis. DNA Cell Biol. 38:905–914. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kheirollahi V, Wasnick RM, Biasin V,
Vazquez-Armendariz AI, Chu X, Moiseenko A, Weiss A, Wilhelm J,
Zhang JS, Kwapiszewska G, et al: Metformin induces lipogenic
differentiation in myofibroblasts to reverse lung fibrosis. Nat
Commun. 10(2987)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Caporarello N, Meridew JA, Jones DL, Tan
Q, Haak AJ, Choi KM, Manlove LJ, Prakash YS, Tschumperlin DJ and
Ligresti G: PGC1α repression in IPF fibroblasts drives a pathologic
metabolic, secretory and fibrogenic state. Thorax. 74:749–760.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Woodley DT: Distinct fibroblasts in the
papillary and reticular dermis: Implications for wound healing.
Dermatol Clin. 35:95–100. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Schruf E, Schroeder V, Kuttruff CA, Weigle
S, Krell M, Benz M, Bretschneider T, Holweg A, Schuler M, Frick M,
et al: Human lung fibroblast-to-myofibroblast transformation is not
driven by an LDH5-dependent metabolic shift towards aerobic
glycolysis. Respir Res. 20(87)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Woodcock HV, Eley JD, Guillotin D, Platé
M, Nanthakumar CB, Martufi M, Peace S, Joberty G, Poeckel D, Good
RB, et al: The mTORC1/4E-BP1 axis represents a critical signaling
node during fibrogenesis. Nat Commun. 10(6)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ebrahimpour A, Shrestha S, Bonnen MD,
Eissa NT, Raghu G and Ghebre YT: Nicotine modulates growth factors
and MicroRNA to promote inflammatory and fibrotic processes. J
Pharmacol Exp Ther. 368:169–178. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Nie Y, Zhang D, Qian F and Wu Y: Baccatin
III ameliorates bleomycin-induced pulmonary fibrosis via
suppression of TGF-β1 production and TGF-β1-induced fibroblast
differentiation. Int Immunopharmacol. 74(105696)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wynn TA: Integrating mechanisms of
pulmonary fibrosis. J Exp Med. 208:1339–1350. 2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Nenov MN, Konakov MV, Teplov IY and Levin
SG: Interleukin-10 facilitates glutamatergic synaptic transmission
and homeostatic plasticity in cultured hippocampal neurons. Int J
Mol Sci. 20(3375)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Krakow S, Crescimone ML, Bartels C,
Wiegering V, Eyrich M, Schlegel PG and Wölfl M: Re-expression of
CD14 in response to a combined IL-10/TLR stimulus defines
monocyte-derived cells with an immunoregulatory phenotype. Front
Immunol. 10(1484)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xiao S, Huang G, Wei Z, Nie K, Liu Z, Deng
C and Wang D: IL-10 Gene-modified human amniotic mesenchymal stem
cells augment regenerative wound healing by multiple synergistic
effects. Stem Cells Int. 2019(9158016)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sheridan MP, Browne JA, Doyle MB,
Fitzsimons T, McGill K and Gormley E: IL-10 suppression of IFN-γ
responses in tuberculin-stimulated whole blood from Mycobacterium
bovis infected cattle. Vet Immunol Immunopathol. 189:36–42.
2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Shamskhou EA, Kratochvil MJ, Orcholski ME,
Nagy N, Kaber G, Steen E, Balaji S, Yuan K, Keswani S, Danielson B,
et al: Hydrogel-based delivery of Il-10 improves treatment of
bleomycin-induced lung fibrosis in mice. Biomaterials. 203:52–62.
2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Raghu G, Collard HR, Egan JJ, Martinez FJ,
Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et
al: An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary
fibrosis: Evidence-based guidelines for diagnosis and management.
Am J Respir Crit Care Med. 183:788–824. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Deterding RR, DeBoer EM, Cidon MJ,
Robinson TE, Warburton D, Deutsch GH and Young LR: Approaching
clinical trials in childhood interstitial lung disease and
pediatric pulmonary fibrosis. Am J Respir Crit Care Med.
200:1219–1227. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Algamdi M, Sadatsafavi M, Fisher JH,
Morisset J, Johannson KA, Fell CD, Kolb M, Manganas H, Cox G,
Gershon AS, et al: Costs of workplace productivity loss in patients
with fibrotic interstitial lung disease. Chest. 156:887–895.
2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wen J, Lin X, Gao W, Qu B, Zuo Y, Liu R
and Yu M: Inhibition of LPA1 Signaling impedes
conversion of human Tenon's fibroblasts into myofibroblasts via
suppressing TGF-β/Smad2/3 signaling. J Ocul Pharmacol Ther.
35:331–340. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Saraiva M and O'Garra A: The regulation of
IL-10 production by immune cells. Nat Rev Immunol. 10:170–181.
2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang Y, Sun SN, Liu Q, Yu YY, Guo J, Wang
K, Xing BC, Zheng QF, Campa MJ, Patz EF Jr, et al: Autocrine
complement inhibits IL10-dependent T-cell-mediated antitumor
immunity to promote tumor progression. Cancer Discov. 6:1022–1035.
2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yang S, Tang X, Sheng X, Xing J and Zhan
W: Analysis of the role of IL-10 in the phagocytosis of
mIgM+ B lymphocytes in flounder (Paralichthys
olivaceus). Fish Shellfish Immunol. 92:813–820. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ramakrishna C, Kujawski M, Chu H, Li L,
Mazmanian SK and Cantin EM: Bacteroides fragilis polysaccharide A
induces IL-10 secreting B and T cells that prevent viral
encephalitis. Nat Commun. 10(2153)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Vora M, Romero LI and Karasek MA:
Interleukin-10 induces E-selectin on small and large blood vessel
endothelial cells. J Exp Med. 184:821–829. 1996.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Qiao J, Liu Z, Dong C, Luan Y, Zhang A,
Moore C, Fu K, Peng J, Wang Y, Ren Z, et al: Targeting Tumors with
IL-10 prevents dendritic cell-mediated CD8+ T cell
apoptosis. Cancer Cell. 35:901–915.e4. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bergeron A, Soler P, Kambouchner M,
Loiseau P, Milleron B, Valeyre D, Hance AJ and Tazi A: Cytokine
profiles in idiopathic pulmonary fibrosis suggest an important role
for TGF-beta and IL-10. Eur Respir J. 22:69–76. 2003.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Papiris SA, Tomos IP, Karakatsani A,
Spathis A, Korbila I, Analitis A, Kolilekas L, Kagouridis K,
Loukides S, Karakitsos P and Manali ED: High levels of IL-6 and
IL-8 characterize early-on idiopathic pulmonary fibrosis acute
exacerbations. Cytokine. 102:168–172. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wollin L, Distler JH, Redente EF, Riches
DW, Stowasser S, Schlenker-Herceg R, Maher TM and Kolb M: Potential
of nintedanib in treatment of progressive fibrosing interstitial
lung diseases. Eur Respir J. 54(1900161)2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Kotlarz D, Beier R, Murugan D,
Diestelhorst J, Jensen O, Boztug K, Pfeifer D, Kreipe H, Pfister
ED, Baumann U, et al: Loss of interleukin-10 signaling and
infantile inflammatory bowel disease: Implications for diagnosis
and therapy. Gastroenterology. 143:347–355. 2012.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Glocker EO, Kotlarz D, Boztug K, Gertz EM,
Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan
D, et al: Inflammatory bowel disease and mutations affecting the
interleukin-10 receptor. N Engl J Med. 361:2033–2045.
2009.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Engelhardt KR, Shah N, Faizura-Yeop I,
Kocacik Uygun DF, Frede N, Muise AM, Shteyer E, Filiz S, Chee R,
Elawad M, et al: Clinical outcome in IL-10- and IL-10
receptor-deficient patients with or without hematopoietic stem cell
transplantation. J Allergy Clin Immunol. 131:825–830.
2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
McDonald S, Reed R and Baricevic-Jones I:
Biologics in Rheumatoid Arthritis Genetics and Genomics Study
Syndicate. Ling S, Plant D and Barton A: Can serum interleukin-17
and interleukin-10 levels predict response to biologic treatments
in patients with rheumatoid arthritis? Rheumatology (Oxford).
58:1872–1873. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Vahl JM, Friedrich J, Mittler S, Trump S,
Heim L, Kachler K, Balabko L, Fuhrich N, Geppert CI, Trufa DI, et
al: Interleukin-10-regulated tumour tolerance in non-small cell
lung cancer. Br J Cancer. 117:1644–1655. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Lopes RL, Borges TJ, Zanin RF and Bonorino
C: IL-10 is required for polarization of macrophages to M2-like
phenotype by mycobacterial DnaK (heat shock protein 70). Cytokine.
85:123–129. 2016.PubMed/NCBI View Article : Google Scholar
|
